REFERENCES
- Verma S, Simpson DM. Peripheral neuropathy in HIV infec-tion. In: Portegies P, Berger J, eds. Handbook of Clinical Neurology. Amsterdam: Elsevier; 2007:129–137.
- Simpson D, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr. 1995;9:153–161.
- Evans SR, Clifford DB, Chen H, et al. HIV-Associated Peripheral Neuropathy in the HAART Era: Results from AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Protocol A5001. Presented at: 16th CROI Conference; February 8–11, 2009; Montreal, QC, Canada.
- Strizki JM, Tremblay C, Xu S, et al. Discovery and chra-cterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49:4911–4919.
- Thompson KA, Churchill MJ, Gorry PR, et al. Astro-cyte specific viral strains in HIV dementia. Ann NeuroL 2004;56(6):873–877.
- Jones G, Zhu Y, Silva C, et al. Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology. 2005;334(2):178–93.
- Keswani SC, Polley M, Pardo CA, et al. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sen-sory neurons. Ann NeuroL 2003;54(3):287–296.
- Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a ccr5 inhibitor, in hiv-1—infected, treatment-experienced patients: AIDS Clin-ical Trials Group 5211. J Infect Dis. 2007;196:304–312.